EverSource Wealth Advisors’s Amneal Pharmaceuticals AMRX Stock Holding History

EverSource Wealth Advisors’s Portfolio AMRX Stock Details AMRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$33.9K	Buy	1,957 +274	+16%	+$3.75K	﹤0.01%	2045
2026 Q1	$20.9K	Buy	1,683 +68	+4%	+$913	﹤0.01%	2477
2025 Q4	$20.4K	Buy	1,615 +32	+2%	+$366	﹤0.01%	2374
2025 Q3	$15.8K	Buy	1,583 +277	+21%	+$2.49K	﹤0.01%	2527
2025 Q2	$10.6K	Buy	1,306 +915	+234%	+$6.9K	﹤0.01%	2772
2025 Q1	$3.28K	Buy	391 +362	+1,248%	+$3.02K	﹤0.01%	2692
2024 Q4	$230	Buy	+29	New	+$243	﹤0.01%	3412
2023 Q1	–	Sell	-671	Closed	-$1.33K	–	2380
2022 Q4	$1.33K	Buy	+671	New	+$1.5K	﹤0.01%	2026

Other funds holding AMRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

TGA

TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

RCMNY

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return

EverSource Wealth Advisors's AMRX Position: Q2 2026 in Review

EverSource Wealth Advisors increased its Amneal Pharmaceuticals (AMRX) stake by 16% in Q2 2026, buying an estimated $3.75K and bringing the position to 1,957 shares worth $33.9K. The position accounts for ﹤0.01% of the portfolio, ranked #2045.

EverSource Wealth Advisors first reported a position in AMRX in Q4 2022 and has held it in 8 quarters since. 311 funds tracked by Wall St. Rank hold AMRX as of Q2 2026.

EverSource Wealth Advisors held 1,957 shares of Amneal Pharmaceuticals worth $33.9K as of Q2 2026.
EverSource Wealth Advisors bought 274 Amneal Pharmaceuticals shares in Q2 2026, an estimated $3.75K.
Amneal Pharmaceuticals made up ﹤0.01% of EverSource Wealth Advisors's portfolio in Q2 2026, its #2045 holding.
EverSource Wealth Advisors first reported a position in Amneal Pharmaceuticals in Q4 2022 and has held it in 8 quarters since.
311 funds tracked by Wall St. Rank held Amneal Pharmaceuticals as of Q2 2026.

Based on EverSource Wealth Advisors's 13F filing for Q2 2026, filed 24 Jul 2026.